2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
10190
Neoplasms
7819
Carcinoma, Non-Small-Cell Lung
5763
Prostatic Neoplasms
5032
Colorectal Neoplasms
4608
Lung Neoplasms
3727
Leukemia, Myeloid, Acute
3104
Neoplasm Metastasis
3086
Multiple Myeloma
3083
Pancreatic Neoplasms
2846
Melanoma
2654
Ovarian Neoplasms
2578
Lymphoma
2571
Carcinoma, Hepatocellular
2483
Stomach Neoplasms
2331
Recurrence
2229
Head and Neck Neoplasms
2106
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2086
Lymphoma, Non-Hodgkin
2058
Leukemia
2013
Brain Neoplasms
1906
Glioblastoma
1799
Colonic Neoplasms
1791
Leukemia, Lymphocytic, Chronic, B-Cell
1771
Rectal Neoplasms
1720
Uterine Cervical Neoplasms
1695
Lymphoma, Follicular
1655
Squamous Cell Carcinoma of Head and Neck
1654
Lymphoma, Large B-Cell, Diffuse
1598
Carcinoma, Renal Cell
1579
Interventions
abemaciclib
1
Trastuzumab
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hormone Receptor Positive Breast Cancer
×
Clear all
NCT02675231
2024-11-26
monarcHER
Eli Lilly and Company
Phase 2
Completed
237 enrolled
25 charts